Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the u...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Valencia, A, Masala, E, Rossi, A, Martino, A, Sanna, A, Buchi, F, Canzian, F, Cilloni, D, Gaidano, V, Voso, M T, Kosmider, O, Fontenay, M, Gozzini, A, Bosi, A, Santini, V
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2014
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3948159/
https://ncbi.nlm.nih.gov/pubmed/24192812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.330
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi